{
  "id": "5e30f8abfbd6abf43b000047",
  "type": "list",
  "question": "Which molecules are inhibited by Gilteritinib?",
  "ideal_answer": "Gilteritinib is a novel, dual FLT3/AXL inhibitor with promising early phase trial data for acute myeloid leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
    "http://www.ncbi.nlm.nih.gov/pubmed/31665578",
    "http://www.ncbi.nlm.nih.gov/pubmed/30053332",
    "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
    "http://www.ncbi.nlm.nih.gov/pubmed/31528345",
    "http://www.ncbi.nlm.nih.gov/pubmed/29669779",
    "http://www.ncbi.nlm.nih.gov/pubmed/29507660",
    "http://www.ncbi.nlm.nih.gov/pubmed/30514344",
    "http://www.ncbi.nlm.nih.gov/pubmed/31069015",
    "http://www.ncbi.nlm.nih.gov/pubmed/28645776",
    "http://www.ncbi.nlm.nih.gov/pubmed/31088841",
    "http://www.ncbi.nlm.nih.gov/pubmed/31454267",
    "http://www.ncbi.nlm.nih.gov/pubmed/29643105",
    "http://www.ncbi.nlm.nih.gov/pubmed/30039554",
    "http://www.ncbi.nlm.nih.gov/pubmed/29498296",
    "http://www.ncbi.nlm.nih.gov/pubmed/30344940",
    "http://www.ncbi.nlm.nih.gov/pubmed/30721452"
  ],
  "snippets": [
    {
      "text": "ASP2215 (gilteritinib) is a novel, dual FLT3/AXL inhibitor with promising early phase trial data (NCT02014558). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29498296",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ex vivo exposure (n = 30) to FLT3 inhibitors, in particular to the FLT3-specific inhibitor gilteritinib, showed that colony-forming capacity was significantly more reduced in FLT3-ITD-AR \u2265 0.5 compared with ITD-AR-low and ITD- patient samples (P < .001). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29669779",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, overexpression of Pim-1 in 32D/TKD enhanced the mTORC1/Mcl-1 pathway and partially protected it from the PI3K/Akt inhibitors or the FLT3 inhibitor gilteritinib to confer the resistance to PI3K/Akt inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29507660",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, we analyzed bone marrow samples from 80 patients with FLT3-ITD relapsed/refractory AML participating in a trial of a novel FLT3 inhibitor, gilteritinib, and demonstrated a relationship between the mutation burden, as detected by the assay, and overall survival. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29643105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib, a novel, highly specific, potent fms-like tyrosine kinase 3/AXL inhibitor, demonstrated antileukemic activity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039554",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Combinations of an AXL inhibitor, cabozantinib or gilteritinib, and an EGFR-TKI were more effective against HCC78R cells than monotherapy with an EGFR-TKI or AXL inhibitor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053332",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Internal tandem duplication (ITD) in Fms-like tyrosine kinase 3 (FLT3) is frequently observed in acute myeloid leukemia (AML). Quizartinib, gilteritinib, and midostaurin are inhibitors against FLT3-ITD that have good efficacy for FLT3-ITD-positive AML patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30344940",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30514344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28645776",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In the FLT3 signaling analyses, gilteritinib inhibited FLT3 __sup__ wt __end_sup__  and FLT3-ITD to a similar degree in HEK293 and Ba/F3 cells, and similarly suppressed FLT3 downstream signaling molecules (including ERK1/2 and STAT5) in both the presence and absence of FL in MOLM-13 cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28645776",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib inhibits FLT3 (STK1 or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30721452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings confirm that FLT3 is a high-value target for treatment of relapsed or refractory acute myeloid leukaemia; based on activity data, gilteritinib at 120 mg/day is being tested in phase 3 trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28645776",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast to other FLT3 inhibitors, FL stimulation had little effect on growth inhibition or apoptosis induction by gilteritinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we investigated the effect of FL on the efficacy of gilteritinib, a FLT3 inhibitor, in AML-derived cells  __i_tag__ in vitro __end_i_tag__  and in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib (ASP2215, Xospata) is a small molecule dual inhibitor of FLT3/AXL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31528345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31528345",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31665578",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Co-crystal structure analysis showed that gilteritinib bound to the ATP-binding pocket of FLT3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effect of Fms-like tyrosine kinase 3 ( FLT3 ) ligand ( FL ) on antitumor activity of gilteritinib , a FLT3 inhibitor , in mice xenografted with FL-overexpressing cells .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In the FLT3 signaling analyses , gilteritinib inhibited FLT3and FLT3-ITD to a similar degree in HEK293 and Ba/F3 cells , and similarly suppressed FLT3 downstream signaling molecules ( including ERK1/2 and STAT5 ) in both the presence and absence of FL in MOLM-13 cells . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here , we investigated the effect of FL on the efficacy of gilteritinib , a FLT3 inhibitor , in AML-derived cellsand in mice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast to other FLT3 inhibitors , FL stimulation had little effect on growth inhibition or apoptosis induction by gilteritinib . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In contrast to other FLT3 inhibitors, FL stimulation had little effect on growth inhibition or apoptosis induction by gilteritinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we investigated the effect of FL on the efficacy of gilteritinib, a FLT3 inhibitor, in AML-derived cells in vitro and in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31692922",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-positive AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib (Xospata\u00ae) is an orally available small molecule receptor tyrosine kinase inhibitor developed by Astellas Pharma in collaboration with Kotobuki Pharmaceutical for the treatment of acute myeloid leukaemia (AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30721452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib inhibits FLT3 (STK1 or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30721452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib is approved in Japan for the treatment of relapsed or refractory AML with FLT3 mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30721452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31665578",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The highly potent and selective FLT3 kinase inhibitor gilteritinib is the first tyrosine kinase inhibitor approved as monotherapy for the treatment of relapsed and/or refractory FLT3-mutated AML.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31454267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib is a highly-specific, potent FLT3/AXL inhibitor with demonstrated activity against FLT3-ITD and FLT3-TKD mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31069015",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31088841",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gilteritinib, a novel, highly specific, potent fms-like tyrosine kinase 3/AXL inhibitor, demonstrated antileukemic activity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30039554",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "FLT3, AXL"
}